Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

March 24, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations detected being significantly...

Read more

Nature Cell’s JointStem Becomes the First Korean Company to Acquire Breakthrough Therapy Designation from the U.S. FDA

March 22, 2025 12:00 PM

Nature Cell Co., Ltd., a leading biotechnology company announced on March 20th that JointStem, currently undergoing clinical trials in the United States, has been granted Breakthrough Therapy Designation (BTD) from the U.S. FDA- the first instance for a Korean company in the field of cell therapy.The Breakthrough Therapy Designation is granted by the FDA to clinical trials that demonstrate a clinically significant improvement over existing...

Read more

Alligator Bioscience Announces Leadership Transition in Clinical Development

March 21, 2025 1:00 PM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end of March 2025. Dr. Ambarkhane has played a key role in advancing Alligator's immune-oncology pipeline and establishing its clinical development organization over the past years. In particular, he led the clinical development of mitazalimab and OPTIMIZE-1, Alligator's Phase 2 trial in metastatic...

Read more

Elizabeth Fraley, CEO of Kinder Ready Offers a Comprehensive Guide to Navigating the Private School Application Process

March 21, 2025 12:00 PM

Navigating the private school application process can be a complex and overwhelming experience for parents. From researching schools and completing applications to preparing for interviews, the journey requires careful planning and insight. To support families in making informed decisions, Elizabeth Fraley Kinder Ready provides a step-by-step guide to simplify the process.Elizabeth Fraley Kinder Ready has established itself as a leader that...

Read more

Board Changes

March 21, 2025 9:30 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, is pleased to announce the appointment of Dr Juho Jalkanen to the Board of Directors as an Executive Director and Mr. Colin Bond to the Board of Directors as a Non-executive Director of...

Read more

Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM

March 21, 2025 8:00 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGMTURKU, FINLAND - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place at BioCity in Turku, Finland, today 21 March 2025. Forty shareholders representing 42,951,148 shares and votes were represented in the meeting. The AGM approved all the proposals...

Read more

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

March 21, 2025 3:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma (CTCL) will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California.The data, previously...

Read more

Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer

March 20, 2025 10:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator.The FDA's ODD provides incentives such as tax...

Read more

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

March 20, 2025 9:15 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces a collaboration with renowned Big Data and analytics leader to enhance the development of its proprietary technology solutions designed to facilitate Rx-to-OTC switches for pharmaceutical products. The collaboration will incorporate an...

Read more

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

March 20, 2025 9:00 AM

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the...

Read more

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

March 20, 2025 3:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma (TCL).T-cell lymphomas include a number of...

Read more

Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected

March 20, 2025 3:20 AM

Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be electedFaron Pharmaceuticals Ltd. (AIM:FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Shareholders' Nomination Board updates its recommendation on number of Board members...

Read more

Bionoid Pharma Announces Filing of OTCQB Application to Enhance Market Visibility and Liquidity

March 19, 2025 11:10 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced that it has submitted an application to uplist from the OTC Pink to the OTCQB Venture Market.The application process involves a thorough review by OTC Markets Group, which assesses the company's financials, governance, and disclosures. Upon approval, Bionoid Pharma will be able to utilize the U.S. Securities and Exchange Commission's (SEC) modernized Rule 15c2-11 framework,...

Read more

Cortland Biomedical Expands Braiding Capabilities with New Flat and Round-Flat-Round Braiders to Drive Medical Device Innovation

March 19, 2025 11:00 AM

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of custom engineering services, has expanded its braiding capabilities with the addition of flat braiding and round-flat-round braiding equipment. This latest investment provides Cortland Biomedical's OEM customers with access to a full suite of braiding technologies, further strengthening the company's position as a trusted...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

March 19, 2025 8:05 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024.Recent HighlightsExtended its collaborations with the University of Virginia and Scripps Research through 2025;Entered into a Clinical Trial Services Agreement with PeriNess...

Read more

Ondine Biomedical Inc. Announces Steriwave enters ICU and related Issue of Shares

March 19, 2025 3:00 AM

Ondine Biomedical Inc. (LON:OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. Treating patients in intensive care units (ICUs) with Ondine's Steriwave® nasal photodisinfection technology would significantly expand the market opportunity for...

Read more

Moolec Received Nasdaq Staff Determination Letter

March 17, 2025 5:00 PM

Moolec Science SA (NASDAQ:MLEC), a public limited liability company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg, having its registered office at 17, Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés de Luxembourg) under registration number B268440 ("Moolec," the "Company," "we," "us" or...

Read more

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

March 17, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia.IGC-AD1 is a combination therapy designed to address agitation in Alzheimer's disease. As a two-API...

Read more

Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm

March 13, 2025 12:15 PM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.Olayinka Oyebola & Co. has worked diligently to complete...

Read more

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

March 13, 2025 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster...

Read more